• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

格雷夫斯眼眶病患者非胆固醇固醇和脂肪酸分析:对与疾病临床表型相关的脂质代谢的见解

Analysis of non-cholesterol sterols and fatty acids in patients with graves' orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease.

作者信息

Matutinović Marija Sarić, Vladimirov Sandra, Gojković Tamara, Djuričić Ivana, Ćirić Jasmina, Žarković Miloš, Ignjatović Svetlana, Kahaly George J, Nedeljković-Beleslin Biljana

机构信息

Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, Serbia.

Department of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, Serbia.

出版信息

J Endocrinol Invest. 2025 Jun;48(6):1333-1342. doi: 10.1007/s40618-025-02556-x. Epub 2025 Mar 18.

DOI:10.1007/s40618-025-02556-x
PMID:40100571
Abstract

PURPOSE

Graves' orbitopathy (GO) is a complex inflammatory disease of the orbit. A potential link between cholesterol metabolism and the occurrence of GO is possible, but still unexplored. This study aims to investigate patients' lipid status, fatty acid content, and cholesterol homeostasis markers, all in relation to the clinical phenotype of GO.

METHODS

This cross-sectional study enrolled 89 consecutive patients with GO of varying degrees of activity and severity. Conventional lipid parameters were measured using routine biochemical methods. Concentrations of cholesterol synthesis and cholesterol absorption markers were analyzed by a GC-FID method. The percentage composition of individual fatty acids was determined by GC-FID. Total concentration of thyrotropin-receptor antibodies was measured by a binding immunoassay (Roche Diagnostics), while their stimulating activity (TSAb) was quantified using a cell-based bioassay (Quidelortho).

RESULTS

HDL-C concentration was significantly lower in patients with an active GO compared to an inactive form of GO (p = 0.032). The ApoB/ApoA1 ratio was significantly higher in a more severe GO (p = 0.029). Also, a positive correlation between LDL-C and TSAb levels (ρ = 0.255, p = 0.019) was observed. Lathosterol concentration significantly increased in more severe GO cases (p = 0.045). Moreover, the level of cholesterol synthesis-to-absorption index (CSI/CAI) positively correlated with CAS score (ρ = 0.232, p = 0.048). Palmitic acid was significantly associated with active GO (p = 0.012). The levels of desmosterol, lathosterol, CSI/CAI, and oleic acid were significantly associated with TSAb levels.

CONCLUSIONS

Alterations in patients' lipid profile and the cholesterol homeostasis were associated with a worse clinical phenotype of GO.

摘要

目的

格雷夫斯眼眶病(GO)是一种复杂的眼眶炎性疾病。胆固醇代谢与GO的发生之间可能存在潜在联系,但仍未得到探索。本研究旨在调查患者的血脂状况、脂肪酸含量和胆固醇稳态标志物,所有这些均与GO的临床表型相关。

方法

这项横断面研究纳入了89例连续的不同活动度和严重程度的GO患者。使用常规生化方法测量传统脂质参数。通过气相色谱 - 火焰离子化检测法(GC - FID)分析胆固醇合成和胆固醇吸收标志物的浓度。通过GC - FID测定单个脂肪酸的百分比组成。促甲状腺素受体抗体的总浓度通过结合免疫测定法(罗氏诊断)测量,而其刺激活性(TSAb)使用基于细胞的生物测定法(Quidelortho)进行定量。

结果

与非活动型GO患者相比,活动型GO患者的高密度脂蛋白胆固醇(HDL - C)浓度显著降低(p = 0.032)。在更严重的GO中,载脂蛋白B/载脂蛋白A1比值显著更高(p = 0.029)。此外,观察到低密度脂蛋白胆固醇(LDL - C)与TSAb水平之间存在正相关(ρ = 0.255,p = 0.019)。在更严重的GO病例中,羊毛甾醇浓度显著升高(p = 0.045)。此外,胆固醇合成与吸收指数(CSI/CAI)水平与临床活动评分(CAS)呈正相关(ρ = 0.232,p = 0.048)。棕榈酸与活动型GO显著相关(p = 0.012)。麦角固醇、羊毛甾醇、CSI/CAI和油酸水平与TSAb水平显著相关。

结论

患者血脂谱和胆固醇稳态的改变与GO更差的临床表型相关。

相似文献

1
Analysis of non-cholesterol sterols and fatty acids in patients with graves' orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease.格雷夫斯眼眶病患者非胆固醇固醇和脂肪酸分析:对与疾病临床表型相关的脂质代谢的见解
J Endocrinol Invest. 2025 Jun;48(6):1333-1342. doi: 10.1007/s40618-025-02556-x. Epub 2025 Mar 18.
2
Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.格雷夫斯病治疗方案与格雷夫斯眼病病程的关系:一项系统评价和荟萃分析。
J Endocrinol Invest. 2016 Nov;39(11):1225-1233. doi: 10.1007/s40618-016-0484-y. Epub 2016 May 24.
3
Patterns of Extraocular Muscle Enlargement in Graves' Orbitopathy and Acromegaly.格雷夫斯眼眶病和肢端肥大症中眼外肌增大的模式。
Thyroid. 2025 Jun;35(6):706-710. doi: 10.1089/thy.2024.0438. Epub 2024 Dec 20.
4
Extraocular muscle index as a novel indicator of inflammatory condition in graves' ophthalmopathy patients.眼外肌指数作为格雷夫斯眼病患者炎症状态的一种新指标。
Front Endocrinol (Lausanne). 2025 May 29;16:1594828. doi: 10.3389/fendo.2025.1594828. eCollection 2025.
5
[Effects of high oleic and different fatty acid composition edible oils on glucose and lipid metabolism in middle-aged and elderly rats].[高油酸及不同脂肪酸组成食用油对中老年大鼠糖脂代谢的影响]
Wei Sheng Yan Jiu. 2025 May;54(3):419-426. doi: 10.19813/j.cnki.weishengyanjiu.2025.03.010.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Radioiodine therapy versus antithyroid medications for Graves' disease.放射性碘治疗与抗甲状腺药物治疗Graves病的比较。
Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Lipid metabolism disturbance and immune dysfunction in HBV-related acute-on-chronic liver failure: a retrospective cohort study.乙型肝炎病毒相关慢加急性肝衰竭中脂质代谢紊乱与免疫功能障碍:一项回顾性队列研究
BMC Gastroenterol. 2025 Jul 1;25(1):444. doi: 10.1186/s12876-025-04004-9.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

引用本文的文献

1
Bibliometrics in thyroid eye disease.甲状腺眼病的文献计量学
J Endocrinol Invest. 2025 Aug 29. doi: 10.1007/s40618-025-02688-0.

本文引用的文献

1
Circulating Fatty Acids Associate with Metabolic Changes in Adolescents Living with Obesity.循环脂肪酸与肥胖青少年的代谢变化相关。
Biomedicines. 2024 Apr 17;12(4):883. doi: 10.3390/biomedicines12040883.
2
Update on Anti-Inflammatory Molecular Mechanisms Induced by Oleic Acid.油酸诱导抗炎分子机制的最新研究进展。
Nutrients. 2023 Jan 1;15(1):224. doi: 10.3390/nu15010224.
3
Pathophysiology of thyroid-associated orbitopathy.甲状腺相关性眼病的病理生理学。
Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101620. doi: 10.1016/j.beem.2022.101620. Epub 2022 Feb 5.
4
Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution.必需脂肪酸及其代谢产物在炎症及其消退的病理生物学中的作用。
Biomolecules. 2021 Dec 14;11(12):1873. doi: 10.3390/biom11121873.
5
The risk factors for Graves' ophthalmopathy.格雷夫斯眼病的危险因素。
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1043-1054. doi: 10.1007/s00417-021-05456-x. Epub 2021 Nov 17.
6
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.他汀类药物治疗格雷夫斯眼病(STAGO):一项 2 期、开放标签、适应性、单中心、随机临床试验。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):733-742. doi: 10.1016/S2213-8587(21)00238-2. Epub 2021 Sep 27.
7
Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.塞尔维亚 Graves 眼病患者功能性促甲状腺素受体抗体的临床价值。
J Endocrinol Invest. 2022 Jan;45(1):189-197. doi: 10.1007/s40618-021-01652-y. Epub 2021 Jul 29.
8
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.2021 年欧洲 Graves 眼病专家组(EUGOGO)Graves 眼病医学管理临床实践指南。
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
9
Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.他汀类药物可降低 Graves 病初诊患者发生眼眶病的风险。
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1325-1332. doi: 10.1210/clinem/dgab070.
10
Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.格雷夫斯眼病的流行病学、自然史、危险因素和预防。
Front Endocrinol (Lausanne). 2020 Nov 30;11:615993. doi: 10.3389/fendo.2020.615993. eCollection 2020.